Raise the Line - Transforming the Way Radiologists Learn - Daniel Arnold, CEO of Medality

Transforming the Way Radiologists Learn - Daniel Arnold, CEO of Medality

11/29/22 • 28 min

“Imaging has really become the tip of the spear of the patient journey,” says Daniel Arnold, CEO of Medality. In order to train future radiologists in this critically important and complex specialty, and keep current practitioners on top of their game, Arnold and his team are on a mission to transform the way radiologists learn by offering an online solution that mimics practicing radiology in the field. “Our goal is to make it easy for radiologists to learn a new subspecialty in just five minutes per day.” In his conversation with host Shiv Gaglani, Arnold touches on how Medality (formerly MRI Online) is connecting radiology practices with people who have the skills they need most. The two also discuss the importance of getting imaging diagnoses correct the first time, why radiologists can't just rely on what they learned in residency and fellowship, and the impact of artificial intelligence and other technological advances in the field. “Being a part of the puzzle around how we disseminate new lifesaving technologies is what really motivates us and gets us excited.”

Mentioned in this episode: https://mrionline.com/

If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

Mentioned in this episode: https://mrionline.com/

If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

Previous Episode

Using Walmart’s Giant Healthcare Footprint to Drive Access and Equity - Dr. John Wigneswaran, Chief Medical Officer at Walmart

“One of the reasons I really wanted to be at Walmart is that you're touching people that truly have a need,” says Dr. John Wigneswaran, the retail giant’s Chief Medical Officer. And giant is not an overstatement. 150 million Americans visit a Walmart every week, and there is a store within ten miles of 90% of the U.S. population. In terms of healthcare, there are roughly 5,000 Walmart pharmacies, 4,000 of which are in medically underserved areas. Walmart visitors also have access to primary and urgent care, labs, x-ray and diagnostics, behavioral health, dental, optometry and hearing services. So, clearly, the company is in a unique position to make a big impact in the healthcare space whatever they choose to do. One of their most recent choices is to boost the participation of rural and underserved communities in clinical research, which Dr. Wigneswaran sees as an extension of their existing mission. “Ultimately, what we're trying to do to is drive safer, high quality and equitable care, and research is just one of the levers,” he tells host Shiv Gaglani. Tune in to learn about the evolution of a growing player in America’s healthcare system which could include initiatives in diabetes, nutrition education, wound care and HIV.

Mentioned in this episode: Walmart Health and Wellness

If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

Next Episode

Solving the Rare Disease Equation - Dr. Alaa Hamed, Global Head of Medical Affairs, Rare Diseases at Sanofi

As we continue our focus on rare diseases on Raise the Line, we’re delighted to be joined by Dr. Alaa Hamed, Global Head of Medical Affairs, Rare Diseases at Sanofi, one of the leading pharmaceutical companies in the world. Although most well known for their focus on lysosomal storage disorders including Gaucher and Pompe disease, Dr. Hamed and his team at Sanofi are also working in adjacent disease spaces depending on the systems affected. “For example, the lysosome in Pompe disease affects the neuromuscular tissues, so we have a neuromuscular disorder interest as well.” In their discussion, Dr. Hamed and host Shiv Gaglani also touch on the efforts Sanofi is making to shorten the diagnostic odyssey for rare disease patients, including building more disease awareness and greater global infrastructure. “From the inception, we thought that having universal access is a key part of the rare disease equation.” You’ll also learn about the challenges of drug development, the importance of maintaining policy incentives to focus on rare diseases, and where innovation is needed most to advance outcomes for patients.

Mentioned in this episode: https://www.sanofi.com/

If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast